Weight Loss – Talk Bio

Lilly’s oral GLP-1 succeeds in first Phase III test, delivering promising weight loss

6 days ago talkbio0Tagged Diabetes Mellitus, Non-Insulin-Dependent, Glucagon-Like Peptide 1, Hemoglobin A1c measurement, Injectables, Oral cavity, orforglipron, Phase 3 Clinical Trials, Safety, Weight Loss

orforglipron, Glucagon-Like Peptide 1, Weight Loss, Oral cavity, orforglipron, Phase 3 Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Hemoglobin A1c measurement, Safety, Injectables

Veru’s Enobosarm Reduces Lean Mass Loss in Patients Taking Wegovy for Weight Reduction

3 months ago talkbio0Tagged Agonist, enobosarm, GLP-1 receptor, Lean mass preservation, Obesity, sarcopenic, semaglutide, Wegovy, Weight Loss

Enobosarm, Wegovy (semaglutide), Lean mass preservation, Weight loss, Sarcopenic obesity, GLP-1 receptor agonist

Novo Nordisk’s Obesity Drug Breakthrough: 22% Weight Loss at Week 36 Boosts Stock by 11%

3 months ago talkbio0Tagged 22%, amycretin, Drug Industry, next-gen, Nordisk, Obesity, semaglutide, Stock Surge, Weight Loss

Novo Nordisk, Obesity drug, 22% weight loss, Stock surge, Next-gen obesity treatment, Amycretin, Semaglutide, Pharmaceutical industry

Hengrui and Kailera’s Obesity Drug HRS9531 Shows Promising Results in Phase 2 Trial

3 months ago talkbio0Tagged GLP-1/GIP receptor dual agonist, Hengrui Pharmaceuticals, Kailera, Obesity, Phase 2 clinical trial, Weight Loss

HRS9531, Obesity treatment, GLP-1/GIP receptor dual agonist, Phase 2 clinical trial, Weight loss, Hengrui Pharmaceuticals, Kailera Therapeutics

GLP-1 Medications: Balancing Efficacy and Concerns Amidst Celebrity Endorsements and Rising Demand

4 months ago talkbio0Tagged agonists, aspects of adverse effects, Diabetes Mellitus, Non-Insulin-Dependent, Employer, Endorsements, Famous Persons, Financial cost, Glucagon-Like Peptide 1, Health Planning, Long-term Safety, Weight Loss

GLP-1 agonists, Weight loss, Type 2 diabetes, Celebrity endorsements, Side effects, Long-term safety, Cost implications, Employer health plans

CagriSema Achieves 22.7% Weight Loss in Phase 3 REDEFINE 1 Trial, Falling Short of 25% Target

4 months ago talkbio0Tagged cagrilintide, CagriSema, Nordisk, Obesity, Phase 3 REDEFINE 1 Trial, semaglutide, Weight Loss

CagriSema, Weight Loss, Phase 3 REDEFINE 1 Trial, Obesity Treatment, Novo Nordisk, Semaglutide, Cagrilintide

Merck Enters Obesity Market with $2 Billion Deal for Chinese Oral GLP-1 Drug

4 months ago talkbio0Tagged Benefit, cardiometabolic, Glucagon-Like Peptide 1, Hansoh Pharma, HS-10535, Merck, Obesity, Oral cavity, Weight Loss

Merck, Obesity, Oral GLP-1, Hansoh Pharma, HS-10535, Weight Loss, Cardiometabolic Benefits

Lilly’s Zepbound Outshines Novo’s Wegovy in First Head-to-Head Weight Loss Study

5 months ago talkbio0Tagged Eli, Eli Lilly, Nordisk, Obesity, SURMOUNT-5, Wegovy, Weight Loss, Zepbound

Eli Lilly, Novo Nordisk, Zepbound, Wegovy, Weight Loss, Obesity Treatment, Head-to-Head Study, SURMOUNT-5

GUBamy, a Weekly Amylin Agonist, Shows Promising Weight Loss and Tolerability in Phase 1 Trial

5 months ago talkbio0Tagged Agonist, Amylin, GUBamy, long-acting, Obesity, phase 1 trial, Weight Loss

Amylin agonist, Obesity treatment, Weight loss, Phase 1 trial, GUBamy, Long-acting amylin agonist

UK Health Secretary Warns Against Misuse of GLP-1 Weight Loss Drugs for Aesthetic Purposes

6 months ago talkbio0Tagged agonists, Cautionary Warning, Esthetics (discipline), Glucagon-Like Peptide 1, health secretary, MHRA, MISUSE, UK, Weight Loss, Weight-Loss Agents

GLP-1 agonists, weight loss drugs, misuse, aesthetic weight loss, UK health secretary, MHRA warnings